Skip to content
DataLookout
Menu

CHIPNCT07511582

Corticosteroids in Hyperinflammatory Phenotype of Critical Illness

StatusRecruiting
PhasePhase 2
SponsorBin Du
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 111 words Show 4 more changesShow less
    • Trial sites expanded: 1 → 11 locations
    • Secondary endpoints: details revised at 2 of 3 entries
    • Study description expanded, about 162 words
    • Publications: details revised at 40 of 40 entries
  2. Notable Recruitment opened
    • Study completion pushed from Apr 1, 2028 to Jun 1, 2028
    • Start date changed from estimate of Apr 1, 2026 to Apr 15, 2026
    • Site details revised
    v3
  3. Notable Primary endpoint(s) modifiedv2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Proportion of patients with a decrease in mean Sequential Organ Failure Assessment (SOFA) score ≥1.4 points from baseline to Day 9
Timeframe: From baseline (Day 1) to Day 9

Secondary (3)

30-day Organ Support Free Days (OSFD)
30-day mortality
Incidence and severity of adverse events and serious adverse events during treatment

Arms and interventions

high dose methylprednisolone groupExperimental

Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

low dose methylprednisolone groupExperimental

Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

placebo groupPlacebo comparator

Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

Drugs: Methylprednisolone (MP), Placebo

Sites

11 sites in 1 country